Hepatic steatosis in women with polycystic ovary syndrome
Abstract Background This multi-center, cross-sectional study intended to explore the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with polycystic ovary syndrome (PCOS). Methods Patients who met th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12902-023-01456-6 |
| _version_ | 1797452327222771712 |
|---|---|
| author | Xinyu Hong Zaixin Guo Qi Yu |
| author_facet | Xinyu Hong Zaixin Guo Qi Yu |
| author_sort | Xinyu Hong |
| collection | DOAJ |
| description | Abstract Background This multi-center, cross-sectional study intended to explore the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with polycystic ovary syndrome (PCOS). Methods Patients who met the PCOS Rotterdam diagnostic criteria were enrolled in 6 centers in China, and age-matched healthy volunteers were also recruited. Data were collected including medical history, physical characteristics, and blood tests (liver function, blood lipids, blood glucose and insulin, sex hormones, etc.). Transvaginal or transrectal ultrasound was employed to identify polycystic ovarian morphology (PCOM). The serological score Liver Fat Score (LFS) >-0.640 was used for the diagnosis of NAFLD, and the diagnosis of MAFLD was made according to the 2020 new definition. Results A total of 217 PCOS patients and 72 healthy controls were included. PCOS patients had impaired glucose and lipid metabolism, higher liver enzymes and LFS. Both NAFLD (33.6%) and MAFLD (42.8%) was more prevalent in PCOS patients than in controls (4.2%, P < 0.001). Logistic regression results showed that HOMA-IR ≥ 3.54 and ALT ≥ 18.2 were independently associated with NAFLD (P < 0.001) and MAFLD (P ≤ 0.001). The prevalence of NAFLD was significantly higher in PCOS patients with free androgen index (FAI) > 8 (53.8% versus 17.4%, P < 0.001) and BMI ≥ 24 kg/m2 (57.3%, 11.3%, P < 0.001). Conclusion The prevalence of NAFLD/MAFLD in PCOS patients was significantly higher than that in healthy controls and was independently associated with HOMA-IR and ALT. PCOS patients with overweight and elevated FAI have a higher prevalence of fatty liver. |
| first_indexed | 2024-03-09T15:07:22Z |
| format | Article |
| id | doaj.art-a777fa2b1bbc4d7bbdea08d7e82ca4e4 |
| institution | Directory Open Access Journal |
| issn | 1472-6823 |
| language | English |
| last_indexed | 2024-03-09T15:07:22Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj.art-a777fa2b1bbc4d7bbdea08d7e82ca4e42023-11-26T13:35:06ZengBMCBMC Endocrine Disorders1472-68232023-09-0123111110.1186/s12902-023-01456-6Hepatic steatosis in women with polycystic ovary syndromeXinyu Hong0Zaixin Guo1Qi Yu2Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical CollegeAbstract Background This multi-center, cross-sectional study intended to explore the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with polycystic ovary syndrome (PCOS). Methods Patients who met the PCOS Rotterdam diagnostic criteria were enrolled in 6 centers in China, and age-matched healthy volunteers were also recruited. Data were collected including medical history, physical characteristics, and blood tests (liver function, blood lipids, blood glucose and insulin, sex hormones, etc.). Transvaginal or transrectal ultrasound was employed to identify polycystic ovarian morphology (PCOM). The serological score Liver Fat Score (LFS) >-0.640 was used for the diagnosis of NAFLD, and the diagnosis of MAFLD was made according to the 2020 new definition. Results A total of 217 PCOS patients and 72 healthy controls were included. PCOS patients had impaired glucose and lipid metabolism, higher liver enzymes and LFS. Both NAFLD (33.6%) and MAFLD (42.8%) was more prevalent in PCOS patients than in controls (4.2%, P < 0.001). Logistic regression results showed that HOMA-IR ≥ 3.54 and ALT ≥ 18.2 were independently associated with NAFLD (P < 0.001) and MAFLD (P ≤ 0.001). The prevalence of NAFLD was significantly higher in PCOS patients with free androgen index (FAI) > 8 (53.8% versus 17.4%, P < 0.001) and BMI ≥ 24 kg/m2 (57.3%, 11.3%, P < 0.001). Conclusion The prevalence of NAFLD/MAFLD in PCOS patients was significantly higher than that in healthy controls and was independently associated with HOMA-IR and ALT. PCOS patients with overweight and elevated FAI have a higher prevalence of fatty liver.https://doi.org/10.1186/s12902-023-01456-6Polycystic ovary syndromeMetabolic dysfunction-associated fatty liver diseaseNonalcoholic fatty liver diseaseHepatic steatosisInsulin resistance |
| spellingShingle | Xinyu Hong Zaixin Guo Qi Yu Hepatic steatosis in women with polycystic ovary syndrome BMC Endocrine Disorders Polycystic ovary syndrome Metabolic dysfunction-associated fatty liver disease Nonalcoholic fatty liver disease Hepatic steatosis Insulin resistance |
| title | Hepatic steatosis in women with polycystic ovary syndrome |
| title_full | Hepatic steatosis in women with polycystic ovary syndrome |
| title_fullStr | Hepatic steatosis in women with polycystic ovary syndrome |
| title_full_unstemmed | Hepatic steatosis in women with polycystic ovary syndrome |
| title_short | Hepatic steatosis in women with polycystic ovary syndrome |
| title_sort | hepatic steatosis in women with polycystic ovary syndrome |
| topic | Polycystic ovary syndrome Metabolic dysfunction-associated fatty liver disease Nonalcoholic fatty liver disease Hepatic steatosis Insulin resistance |
| url | https://doi.org/10.1186/s12902-023-01456-6 |
| work_keys_str_mv | AT xinyuhong hepaticsteatosisinwomenwithpolycysticovarysyndrome AT zaixinguo hepaticsteatosisinwomenwithpolycysticovarysyndrome AT qiyu hepaticsteatosisinwomenwithpolycysticovarysyndrome |